Protagonist Therapeutics Inc (PTGX)

Pretax margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	165,436	-78,955	-140,484	-137,611	-140,188	-127,393	-130,106	-132,678	-122,483	-125,551	-107,530	-81,489	-68,939	-64,845	-62,604	-71,352	-83,834	-77,850	-75,869	-68,093
Revenue (ttm)	US$ in thousands	315,090	60,137	123	123	982	26,704	35,221	45,507	46,913	27,380	24,330	27,139	31,091	28,549	25,678	12,604	6,408	4,321	3,955	10,051
Pretax margin		52.50%	-131.29%	-114,214.63%	-111,878.86%	-14,275.76%	-477.06%	-369.40%	-291.56%	-261.09%	-458.55%	-441.96%	-300.27%	-221.73%	-227.14%	-243.80%	-566.11%	-1,308.27%	-1,801.67%	-1,918.31%	-677.47%

March 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $165,436K ÷ $315,090K
= 52.50%

Protagonist Therapeutics Inc's pretax margin has shown significant variability over the past few quarters, ranging from extremely negative figures to a notably high positive percentage in the most recent period. The pretax margin was adversely impacted in previous quarters, with values as low as -131.29% to as high as -114,214.63% due to higher expenses or exceptional items that greatly exceeded the company's operating income.

However, the pretax margin dramatically improved to 52.50% in the most recent quarter, possibly indicating better control over operating expenses or higher revenue generation. It is essential to further investigate the reasons behind this significant improvement to determine if it is sustainable or if it was influenced by one-time factors. Overall, monitoring the trend of Protagonist Therapeutics Inc's pretax margin over time will be crucial for assessing the company's financial performance and profitability.